Table of Contents Author Guidelines Submit a Manuscript
AIDS Research and Treatment
Volume 2012, Article ID 634523, 10 pages
http://dx.doi.org/10.1155/2012/634523
Research Article

The Cancer-Associated Virus Landscape in HIV Patients with Oral Hairy Leukoplakia, Kaposi's Sarcoma, and Non-Hodgkin Lymphoma

1Neurobiology and Pain Therapeutics Section, Laboratory of Sensory Biology, National Institute of Dental and Craniofacial Research, Bethesda, MD 20893, USA
2Critical Care Medicine Department, Clinical Center, Bethesda, MD 20892, USA
3Laboratory of Cell and Developmental Biology, National Institute of Dental and Craniofacial Research, Bethesda, MD 20892, USA
4Department of Orofacial Sciences, School of Dentistry, University of California, San Francisco, San Francisco, CA 94143, USA

Received 7 May 2012; Revised 13 June 2012; Accepted 1 July 2012

Academic Editor: Robert R. Redfield

Copyright © 2012 Peter D. Burbelo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. M. Parkin, “The global health burden of infection-associated cancers in the year 2002,” International Journal of Cancer, vol. 118, no. 12, pp. 3030–3044, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. P. S. Moore and Y. Chang, “Why do viruses cause cancer? Highlights of the first century of human tumour virology,” Nature Reviews Cancer, vol. 10, no. 12, pp. 878–889, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. E. A. Engels, R. J. Biggar, H. I. Hall et al., “Cancer risk in people infected with human immunodeficiency virus in the United States,” International Journal of Cancer, vol. 123, no. 1, pp. 187–194, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. J. J. Goedert, T. R. Coté, P. Virgo et al., “Spectrum of AIDS-associated malignant disorders,” The Lancet, vol. 351, no. 9119, pp. 1833–1839, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Patel, D. L. Hanson, P. S. Sullivan et al., “Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003,” Annals of Internal Medicine, vol. 148, no. 10, pp. 728–736, 2008. View at Google Scholar · View at Scopus
  6. M. J. Silverberg, C. Chao, W. A. Leyden et al., “HIV infection and the risk of cancers with and without a known infectious cause,” AIDS, vol. 23, no. 17, pp. 2337–2345, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. M. S. Shiels, R. M. Pfeiffer, M. H. Gail et al., “Cancer burden in the HIV-infected population in the United States,” Journal of the National Cancer Institute, vol. 103, no. 9, pp. 753–762, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. P. D. Burbelo, K. H. Ching, K. E. Bren, and M. J. Iadarola, “Searching for biomarkers: humoral response profiling with luciferase immunoprecipitation systems,” Expert Review of Proteomics, vol. 8, no. 3, pp. 309–316, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Zumbach, M. Hoffmann, T. Kahn et al., “Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-and-neck squamous-cell carcinoma,” International Journal of Cancer, vol. 85, no. 6, pp. 815–818, 2000. View at Publisher · View at Google Scholar
  10. R. Rosales, M. López-Contreras, and R. R. Cortes, “Antibodies against human papillomavirus (HPV) type 16 and 18 E2, E6 and E7 proteins in sera: correlation with presence of papillomavirus DNA,” Journal of Medical Virology, vol. 65, no. 4, pp. 736–744, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. K. G. Paulson, J. J. Carter, L. G. Johnson et al., “Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients,” Cancer Research, vol. 70, no. 21, pp. 8388–8397, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. P. D. Burbelo, E. Meoli, H. P. Leahy et al., “Anti-HTLV antibody profiling reveals an antibody signature for HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP),” Retrovirology, vol. 5, article 96, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Enose-Akahata, A. Abrams, K. R. Johnson et al., “Quantitative differences in HTLV-I antibody responses: classification and relative risk assessment for asymptomatic carriers and ATL and HAM/TSP patients from Jamaica,” Blood, vol. 119, no. 12, pp. 2829–2836, 2012. View at Publisher · View at Google Scholar
  14. P. D. Burbelo, A. T. Issa, K. H. Ching et al., “Distinct profiles of antibodies to Kaposi sarcoma-associated herpesvirus antigens in patients with Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma,” Journal of Infectious Diseases, vol. 201, no. 12, pp. 1919–1922, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. J. I. Cohen, E. S. Jaffe, J. K. Dale et al., “Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States,” Blood, vol. 117, no. 22, pp. 5835–5849, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Mendoza, S. A. Johnson, B. A. Peterson et al., “Comprehensive analysis of unique cases with extraordinary control over HIV replication,” Blood, vol. 119, no. 20, pp. 4645–4655, 2012. View at Publisher · View at Google Scholar
  17. P. D. Burbelo, K. E. Bren, K. H. Ching et al., “LIPS arrays for simultaneous detection of antibodies against partial and whole proteomes of HCV, HIV and EBV,” Molecular BioSystems, vol. 7, no. 5, pp. 1453–1462, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. P. D. Burbelo, K. H. Ching, T. L. Mattson, J. S. Light, L. R. Bishop, and J. A. Kovacs, “Rapid antibody quantification and generation of whole proteome antibody response profiles using LIPS (luciferase immunoprecipitation systems),” Biochemical and Biophysical Research Communications, vol. 352, no. 4, pp. 889–895, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. P. D. Burbelo, J. A. Kovacs, K. H. Ching et al., “Proteome-wide anti-hepatitis C virus (HCV) and anti-HIV antibody profiling for predicting and monitoring the response to HCV therapy in HIV-coinfected patients,” Journal of Infectious Diseases, vol. 202, no. 6, pp. 894–898, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. A. T. Makuria, S. Raghuraman, P. D. Burbelo et al., “The clinical relevance of persistent recombinant immunoblot assay-indeterminate reactions: insights into the natural history of hepatitis C virus infection and implications fordonor counseling,” Transfusion. In press. View at Publisher · View at Google Scholar
  21. P. D. Burbelo, H. P. Leahy, S. Groot et al., “Four-antigen mixture containing V-cyclin for serological screening of human herpesvirus 8 infection,” Clinical and Vaccine Immunology, vol. 16, no. 5, pp. 621–627, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. P. D. Burbelo, R. Goldman, and T. L. Mattson, “A simplified immunoprecipitation method for quantitatively measuring antibody responses in clinical sera samples by using mammalian-produced Renilla luciferase-antigen fusion proteins,” BMC Biotechnology, vol. 5, article 22, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. P. D. Burbelo, K. H. Ching, C. M. Klimavicz, and M. J. Iadarola, “Antibody profiling by Luciferase Immunoprecipitation Systems (LIPS),” Journal of Visualized Experiments, no. 32, article 1549, 2009. View at Google Scholar · View at Scopus
  24. E. A. Engels, M. Frisch, J. J. Goedert, R. J. Biggar, and R. W. Miller, “Merkel cell carcinoma and HIV infection,” The Lancet, vol. 359, no. 9305, pp. 497–498, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. J. S. Greenspan, D. Greenspan, and E. T. Lennette, “Replication of Epstein-Barr virus within the epithelial cells of oral “hairy” leukoplakia, an AIDS-associated lesion,” The New England Journal of Medicine, vol. 313, no. 25, pp. 1564–1571, 1985. View at Google Scholar · View at Scopus
  26. J. M. Binley, P. J. Klasse, Y. Cao et al., “Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1,” Journal of Virology, vol. 71, no. 4, pp. 2799–2809, 1997. View at Google Scholar · View at Scopus
  27. S. A. Strathdee, J. W. Frank, J. McLaughlin et al., “Quantitative measures of human immunodeficiency virus-specific antibodies predict progression to AIDS,” Journal of Infectious Diseases, vol. 172, no. 5, pp. 1375–1379, 1995. View at Google Scholar · View at Scopus
  28. F. P. Kroon, J. T. van Dissel, J. C. de Jong, and R. van Furth, “Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes,” AIDS, vol. 8, no. 4, pp. 469–476, 1994. View at Google Scholar · View at Scopus
  29. F. P. Kroon, J. T. van Dissel, J. C. de Jong, K. Zwinderman, and R. van Furth, “Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study,” Vaccine, vol. 18, no. 26, pp. 3040–3049, 2000. View at Google Scholar · View at Scopus
  30. J. N. Martin, D. E. Ganem, D. H. Osmond, K. A. Page-Shafer, D. Macrae, and D. H. Kedes, “Sexual transmission and the natural history of human herpesvirus 8 infection,” The New England Journal of Medicine, vol. 338, no. 14, pp. 948–954, 1998. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Casper, A. Wald, J. Pauk, S. R. Tabet, L. Corey, and C. L. Celum, “Correlates of prevalent and incident Kaposi's sarcoma-associated herpesvirus infection in men who have sex with men,” Journal of Infectious Diseases, vol. 185, no. 7, pp. 990–993, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. N. H. T. M. Dukers, N. Renwick, M. Prins et al., “Risk factors for human herpesvirus 8 seropositivity and seroconversion in a cohort of homosexual men,” American Journal of Epidemiology, vol. 151, no. 3, pp. 213–224, 2000. View at Google Scholar · View at Scopus
  33. R. M. Greenblatt, L. P. Jacobson, A. M. Levine et al., “Human herpesvirus 8 infection and Kaposi's sarcoma among human immunodeficiency virus-infected and -uninfected women,” Journal of Infectious Diseases, vol. 183, no. 7, pp. 1130–1134, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Pauk, M. L. Huang, S. J. Brodie et al., “Mucosal shedding of human herpesvirus 8 in men,” The New England Journal of Medicine, vol. 343, no. 19, pp. 1369–1377, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. D. Zheng, J. Wan, Y. G. Cho et al., “Comparison of humoral immune responses to Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus using a viral proteome microarray,” Journal of Infectious Diseases, vol. 204, no. 11, pp. 1683–1691, 2011. View at Publisher · View at Google Scholar
  36. E. Piriou, K. Van Dort, N. M. Nanlohy, M. H. J. Van Oers, F. Miedema, and D. Van Baarle, “Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma,” Blood, vol. 106, no. 9, pp. 3166–3174, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. D. van Baarle, E. Hovenkamp, M. F. C. Callan et al., “Dysfunctional Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma,” Blood, vol. 98, no. 1, pp. 146–155, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. H. M. Chun, M. P. Roediger, K. H. Hullsiek et al., “Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters,” Journal of Infectious Diseases, vol. 205, no. 2, pp. 185–193, 2012. View at Publisher · View at Google Scholar
  39. A. P. Kourtis, M. Bulterys, D. J. Hu, and D. J. Jamieson, “HIV-HBV coinfection—a global challenge,” The New England Journal of Medicine, vol. 366, no. 19, pp. 1749–1752, 2012. View at Publisher · View at Google Scholar
  40. A. Wasley, D. Kruszon-Moran, W. Kuhnert et al., “The prevalence of hepatitis B virus infection in the united states in the era of vaccination,” Journal of Infectious Diseases, vol. 202, no. 2, pp. 192–201, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. M. L. Landrum, K. H. Hullsiek, A. Ganesan et al., “Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals,” AIDS, vol. 24, no. 4, pp. 545–555, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. P. Appleby, V. Beral, R. Newton, G. Reeves, and L. Carpenter, “Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults,” Journal of the National Cancer Institute, vol. 92, no. 22, pp. 1823–1830, 2000. View at Google Scholar · View at Scopus
  43. A. E. Gates and L. D. Kaplan, “AIDS malignancies in the era of highly active antiretroviral therapy,” Oncology, vol. 16, no. 4, pp. 441–459, 2002. View at Google Scholar · View at Scopus
  44. C. Smith, C A. Sabin, J. D. Lundgren et al., “Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study,” AIDS, vol. 24, no. 10, pp. 1537–1548, 2010. View at Publisher · View at Google Scholar · View at Scopus